Rejection versus escape: the tumor MHC dilemma

Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen

(2016) R. Andersen et al.   CLINICAL CANCER RESEARCH

The urgent need to recover MHC class I in cancers for effective immunotherapy

(2016) Federico Garrido et al.   CURRENT OPINION IN IMMUNOLOGY

The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration

(2016) Francisco Perea et al.   INTERNATIONAL JOURNAL OF CANCER

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targetless T cells in cancer immunotherapy

(2016) Per thor Straten et al.   Journal for ImmunoTherapy of Cancer

Immuno-regulatory antibodies for the treatment of cancer

(2015) Jamie Honeychurch et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Adenovirus expressing β2-microglobulin recovers HLA class I expression and antitumor immunity by increasing T-cell recognition

(2014) A B del Campo et al.   CANCER GENE THERAPY

MHC Class I Loss Is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer That Is Reversed by Interferon and Selumetinib Treatment In Vitro

(2014) T. E. Angell et al.   CLINICAL CANCER RESEARCH

CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire

(2014) L. Robert et al.   CLINICAL CANCER RESEARCH

Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype

(2014) Federico Garrido et al.   INTERNATIONAL JOURNAL OF CANCER

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment

(2014) Stefani Spranger et al.   Journal for ImmunoTherapy of Cancer

Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma

(2013) Ana B. del Campo et al.   INTERNATIONAL JOURNAL OF CANCER

Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial

(2012) A Tikidzhieva et al.   BRITISH JOURNAL OF CANCER

Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes

(2012) Monica Bernal et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

IFN-  in the Treatment of Melanoma

(2012) A. A. Tarhini et al.   JOURNAL OF IMMUNOLOGY

Antigen Spreading Contributes to MAGE Vaccination-Induced Regression of Melanoma Metastases

(2011) Véronique Corbière et al.   CANCER RESEARCH

Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes

(2011) Rafael Carretero et al.   INTERNATIONAL JOURNAL OF CANCER

Bacillus Calmette-Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class I-deficient tumor cells

(2010) Rafael Carretero et al.   INTERNATIONAL JOURNAL OF CANCER

Efficient Recovery of HLA Class I Expression in Human Tumor Cells After Beta2-Microglobulin Gene Transfer Using Adenoviral Vector: Implications for Cancer Immunotherapy

(2009) A. B. del Campo et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy

(2008) Rafael Carretero et al.   IMMUNOGENETICS